Literature DB >> 28355116

Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma.

Andreas Ranft1, Corinna Seidel1, Christiane Hoffmann1, Michael Paulussen1, Ann-Christin Warby1, Henk van den Berg1, Ruth Ladenstein1, Claudia Rossig1, Uta Dirksen1, Dieter Rosenbaum1, Herbert Juergens1.   

Abstract

Purpose Significantly improved survival rates in patients with Ewing sarcoma have raised interest in accessing the quality of long-term survivorship. In this study, subjective and objective measurement tools, preclassified as physical or mental scores, were used to assess clinicofunctional outcome and physical activity after intensive bone tumor treatment. Methods Long-term outcome of 618 survivors from consecutive Ewing sarcoma trials was assessed by the Toronto Extremity Salvage Score, Short-Form Health Survey (SF-36), Brief Symptom Inventory (BSI), and Rosenberg Self-Esteem Scale questionnaires and by the accelerometric StepWatch 3 Activity Monitor. Prospective measurements were correlated retrospectively with standardized primary trial data. Results were compared with 316 nonrandom healthy peers by using effect sizes ( d). Median observation time was 12.9 years from primary diagnosis (range, 3.7 to 31.2 years). Results Absolute subjective scores were moderate to good for survivors. Compared with control subjects, unfavorable outcome was shown on physical Toronto Extremity Salvage Score, SF-36 Physical Component Summary, and BSI-Somatization scales (| d| ≥ 0.50; P < .01), in contrast to SF-36 Mental Component Summary, BSI-Anxiety, BSI-Depression, and Rosenberg Self-Esteem Scale mental scales (| d| ≤ 0.31). Survivors were less active than control subjects, as demonstrated by a step count difference of 1,742 steps per day ( d = -0.43; P < .01); however, on average, the recommended level for an active lifestyle was achieved (≥ 10,000 steps). Location of pelvic tumor was the major inferior disease-specific prognostic factor in physical scores ( P < .01), whereas nondisease-specific inferior factors in questionnaires were older age and female sex ( P < .01). Conclusion Survivors of Ewing sarcoma apparently returned to a normal life with minor limitations. Observed reductions in physical scores should be a focus in future research to optimize treatment strategies to reduce a negative impact on the quality of survivorship.

Entities:  

Mesh:

Year:  2017        PMID: 28355116     DOI: 10.1200/JCO.2016.70.6226

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

Review 1.  Small round cell sarcomas.

Authors:  Florencia Cidre-Aranaz; Sarah Watson; James F Amatruda; Takuro Nakamura; Olivier Delattre; Enrique de Alava; Uta Dirksen; Thomas G P Grünewald
Journal:  Nat Rev Dis Primers       Date:  2022-10-06       Impact factor: 65.038

2.  Physical activity in 9-15 year-old pediatric cancer survivors compared to a nationwide sample.

Authors:  Miriam Götte; Simon Basteck; Ronja Beller; Gabriele Gauß; Steffen Schmidt; Alexander Burchartz; Simon Kolb; May Grydeland; Dirk Reinhardt
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-12       Impact factor: 4.322

3.  How Do the Outcomes of Radiation-Associated Pelvic and Sacral Bone Sarcomas Compare to Primary Osteosarcomas following Surgical Resection?

Authors:  Alexander L Lazarides; Zachary D C Burke; Manit K Gundavda; Rostislav Novak; Michelle Ghert; David A Wilson; Peter S Rose; Philip Wong; Anthony M Griffin; Peter C Ferguson; Jay S Wunder; Matthew T Houdek; Kim M Tsoi
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

Review 4.  Advances in the Functional Assessment of Patients with Sarcoma.

Authors:  Duncan C Ramsey; Kenneth R Gundle
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.

Authors:  Safia K Ahmed; R Lor Randall; Steven G DuBois; William S Harmsen; Mark Krailo; Karen J Marcus; Katherine A Janeway; David S Geller; Joel I Sorger; Richard B Womer; Linda Granowetter; Holcombe E Grier; Richard G Gorlick; Nadia N I Laack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-08-24       Impact factor: 7.038

6.  CORR Insights®: Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.

Authors:  Steven Gitelis
Journal:  Clin Orthop Relat Res       Date:  2020-02       Impact factor: 4.755

7.  What Are the Minimum Clinically Important Differences in SF-36 Scores in Patients with Orthopaedic Oncologic Conditions?

Authors:  Koichi Ogura; Mohamed A Yakoub; Alexander B Christ; Tomohiro Fujiwara; Zarko Nikolic; Patrick J Boland; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2020-09       Impact factor: 4.755

Review 8.  A Critical Review of the Impact of Sarcoma on Psychosocial Wellbeing.

Authors:  Lesley Storey; Lorna A Fern; Ana Martins; Mary Wells; Lindsey Bennister; Craig Gerrand; Maria Onasanya; Jeremy S Whelan; Rachael Windsor; Julie Woodford; Rachel M Taylor
Journal:  Sarcoma       Date:  2019-02-17

9.  Characteristics and prognosis of pelvic Ewing sarcoma: a SEER population-based study.

Authors:  Li Chen; Cheng Long; Jiaxin Liu; Fei Xing; Xin Duan
Journal:  PeerJ       Date:  2019-09-17       Impact factor: 2.984

10.  Minimal clinically important differences in SF-36 global score: Current value in orthopedic oncology.

Authors:  Koichi Ogura; Meredith K Bartelstein; Mohamed A Yakoub; Zarko Nikolic; Patrick J Boland; John H Healey
Journal:  J Orthop Res       Date:  2020-12-20       Impact factor: 3.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.